Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of LNK01001 in active rheumatoid arthritis with inadequate response to bDMARDs
CTR20232969Phase 3Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zemprocitinib in rheumatoid arthritis (RA), sponsored by Lynk Pharmaceuticals. Started Dec 2023; status: completed.
02
Drugs
zemprocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20232969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232969.